Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285082488> ?p ?o ?g. }
- W4285082488 endingPage "e1188" @default.
- W4285082488 startingPage "e1179" @default.
- W4285082488 abstract "BackgroundThe most effective treatment for advanced AIDS-associated Kaposi sarcoma is paclitaxel or pegylated liposomal doxorubicin (PLD); neither is routinely used in sub-Saharan Africa due to limited availability and high cost. We examined the clinical impact, costs, and cost-effectiveness of paclitaxel or PLD in Kenya, compared with etoposide or bleomycin–vincristine.MethodsIn this study, we use the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)—International Model to project clinical outcomes and costs among people living with HIV and advanced Kaposi sarcoma on antiretroviral therapy. We compared four different treatment strategies: etoposide, bleomycin–vincristine, paclitaxel, or PLD. We derived cohort characteristics and costs from the Kenyan Academic Model for Providing Access to Healthcare network, and adverse events, efficacy, and mortality from clinical trials. We projected model outcomes over a lifetime and included life expectancy, per-person lifetime costs, and incremental cost-effectiveness ratios (ICERs). We conducted budget impact analysis for 5-year total costs and did deterministic and probabilistic sensitivity analyses to evaluate the effect of uncertainty in input parameters.FindingsWe found that paclitaxel would be more effective than bleomycin–vincristine and would increase life expectancy by 4·2 years per person. PLD would further increase life expectancy by 0·6 years per person. Paclitaxel would be the most cost-effective strategy (ICER US$380 per year-of-life-saved compared with bleomycin–vincristine) and would remain cost-effective across a range of scenarios. PLD would be cost-effective compared with paclitaxel if its price were reduced to $100 per cycle (base case $180 per cycle). Implementing paclitaxel instead of bleomycin–vincristine would save approximately 6400 life-years and would increase the overall 5-year Kenyan health-care costs by $3·7 million; increased costs would be primarily related to ongoing HIV care given improved survival.InterpretationPaclitaxel would substantially increase life expectancy and be cost-effective compared with bleomycin–vincristine for advanced AIDS-associated Kaposi sarcoma in Kenya and should be the standard of care. PLD would further improve survival and be cost-effective with a 44% price reduction.FundingUS National Institutes of Health and Massachusetts General Hospital.TranslationFor the Swahili translation of the abstract see Supplementary Materials section." @default.
- W4285082488 created "2022-07-14" @default.
- W4285082488 creator A5004055853 @default.
- W4285082488 creator A5011059813 @default.
- W4285082488 creator A5012446068 @default.
- W4285082488 creator A5013090706 @default.
- W4285082488 creator A5028224724 @default.
- W4285082488 creator A5033234285 @default.
- W4285082488 creator A5042084556 @default.
- W4285082488 creator A5056270074 @default.
- W4285082488 creator A5059483556 @default.
- W4285082488 creator A5059731511 @default.
- W4285082488 creator A5061118173 @default.
- W4285082488 creator A5067655089 @default.
- W4285082488 creator A5074313423 @default.
- W4285082488 creator A5083442290 @default.
- W4285082488 creator A5083960991 @default.
- W4285082488 date "2022-08-01" @default.
- W4285082488 modified "2023-09-30" @default.
- W4285082488 title "Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis" @default.
- W4285082488 cites W1840531404 @default.
- W4285082488 cites W1962046702 @default.
- W4285082488 cites W2001877203 @default.
- W4285082488 cites W2005519324 @default.
- W4285082488 cites W2018989052 @default.
- W4285082488 cites W2059067102 @default.
- W4285082488 cites W2078465138 @default.
- W4285082488 cites W2089820607 @default.
- W4285082488 cites W2102148935 @default.
- W4285082488 cites W2107248017 @default.
- W4285082488 cites W2121255260 @default.
- W4285082488 cites W2144204878 @default.
- W4285082488 cites W2165837635 @default.
- W4285082488 cites W2167825902 @default.
- W4285082488 cites W2266461706 @default.
- W4285082488 cites W2297626685 @default.
- W4285082488 cites W2310218779 @default.
- W4285082488 cites W2509578420 @default.
- W4285082488 cites W2519603001 @default.
- W4285082488 cites W2769201756 @default.
- W4285082488 cites W2901387968 @default.
- W4285082488 cites W2911402850 @default.
- W4285082488 cites W2916496948 @default.
- W4285082488 cites W2939934481 @default.
- W4285082488 cites W2945433359 @default.
- W4285082488 cites W2972556549 @default.
- W4285082488 cites W2987270357 @default.
- W4285082488 cites W3008567976 @default.
- W4285082488 cites W3009372262 @default.
- W4285082488 cites W3010235078 @default.
- W4285082488 cites W3010313261 @default.
- W4285082488 cites W3087568882 @default.
- W4285082488 cites W3152877990 @default.
- W4285082488 doi "https://doi.org/10.1016/s2214-109x(22)00242-x" @default.
- W4285082488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35839816" @default.
- W4285082488 hasPublicationYear "2022" @default.
- W4285082488 type Work @default.
- W4285082488 citedByCount "4" @default.
- W4285082488 countsByYear W42850824882022 @default.
- W4285082488 countsByYear W42850824882023 @default.
- W4285082488 crossrefType "journal-article" @default.
- W4285082488 hasAuthorship W4285082488A5004055853 @default.
- W4285082488 hasAuthorship W4285082488A5011059813 @default.
- W4285082488 hasAuthorship W4285082488A5012446068 @default.
- W4285082488 hasAuthorship W4285082488A5013090706 @default.
- W4285082488 hasAuthorship W4285082488A5028224724 @default.
- W4285082488 hasAuthorship W4285082488A5033234285 @default.
- W4285082488 hasAuthorship W4285082488A5042084556 @default.
- W4285082488 hasAuthorship W4285082488A5056270074 @default.
- W4285082488 hasAuthorship W4285082488A5059483556 @default.
- W4285082488 hasAuthorship W4285082488A5059731511 @default.
- W4285082488 hasAuthorship W4285082488A5061118173 @default.
- W4285082488 hasAuthorship W4285082488A5067655089 @default.
- W4285082488 hasAuthorship W4285082488A5074313423 @default.
- W4285082488 hasAuthorship W4285082488A5083442290 @default.
- W4285082488 hasAuthorship W4285082488A5083960991 @default.
- W4285082488 hasBestOaLocation W42850824881 @default.
- W4285082488 hasConcept C112930515 @default.
- W4285082488 hasConcept C126322002 @default.
- W4285082488 hasConcept C133925201 @default.
- W4285082488 hasConcept C143998085 @default.
- W4285082488 hasConcept C2776232574 @default.
- W4285082488 hasConcept C2776694085 @default.
- W4285082488 hasConcept C2776755627 @default.
- W4285082488 hasConcept C2777292972 @default.
- W4285082488 hasConcept C2779429289 @default.
- W4285082488 hasConcept C2908647359 @default.
- W4285082488 hasConcept C3019080777 @default.
- W4285082488 hasConcept C71924100 @default.
- W4285082488 hasConcept C99454951 @default.
- W4285082488 hasConceptScore W4285082488C112930515 @default.
- W4285082488 hasConceptScore W4285082488C126322002 @default.
- W4285082488 hasConceptScore W4285082488C133925201 @default.
- W4285082488 hasConceptScore W4285082488C143998085 @default.
- W4285082488 hasConceptScore W4285082488C2776232574 @default.
- W4285082488 hasConceptScore W4285082488C2776694085 @default.
- W4285082488 hasConceptScore W4285082488C2776755627 @default.
- W4285082488 hasConceptScore W4285082488C2777292972 @default.